These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

243 related articles for article (PubMed ID: 25335522)

  • 1. Pediatric psychopharmacological research in the post EU regulation 1901/2006 era.
    Schmäl C; Becker K; Berg R; Brünger M; Lehmkuhl G; Oehler KU; Ruppert T; Staudter C; Trott GE; Dittmann RW
    Z Kinder Jugendpsychiatr Psychother; 2014 Nov; 42(6):441-9. PubMed ID: 25335522
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [The effects of the 12th and 14th amendments to the AMG (Medical Preparations Act) on paediatric pharmaceutical research--a survey of the new regulations].
    Kölch M; Lippert HD; Fegert JM
    Z Kinder Jugendpsychiatr Psychother; 2006 Mar; 34(2):117-26. PubMed ID: 16610597
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Drug therapy in child and adolescent psychiatry in Germany between ethical as well as social and legal conflicts].
    Gerlach M; Warnke A
    Z Kinder Jugendpsychiatr Psychother; 2016; 44(4):249-55. PubMed ID: 27434686
    [No Abstract]   [Full Text] [Related]  

  • 4. [The new German drug market law AMNOG from a child and adolescent psychiatry perspective].
    Dittmann RW
    Nervenarzt; 2016 Apr; 87(4):367-75. PubMed ID: 26992908
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Moving toward a paradigm shift in the regulatory requirements for pediatric medicines.
    Chin WW; Joos A
    Eur J Pediatr; 2016 Dec; 175(12):1881-1891. PubMed ID: 27646479
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Pediatric drug development: ICH harmonized tripartite guideline E11 within the United States of America, the European Union, and Japan].
    Pflieger M; Bertram D
    Arch Pediatr; 2014 Oct; 21(10):1129-38. PubMed ID: 25175054
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The EU paediatric regulation: effects on paediatric psychopharmacology in Europe.
    Stoyanova-Beninska VV; Wohlfarth T; Isaac M; Kalverdijk LJ; van den Berg H; Gispen-de Wied C
    Eur Neuropsychopharmacol; 2011 Aug; 21(8):565-70. PubMed ID: 20621456
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The EU-regulation on medicinal products for paediatric use: impacts on child and adolescent psychiatry and clinical research with minors.
    Kölch M; Schnoor K; Fegert JM
    Eur Child Adolesc Psychiatry; 2007 Jun; 16(4):229-35. PubMed ID: 17417746
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Regulatory issues in pediatric psychopharmacology.
    Laughren TP
    J Am Acad Child Adolesc Psychiatry; 1996 Oct; 35(10):1276-82. PubMed ID: 8885581
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Challenges and opportunities in bringing new medications to market for pediatric patients.
    Upadhyaya HP; Gault L; Allen AJ
    J Am Acad Child Adolesc Psychiatry; 2009 Nov; 48(11):1056-1059. PubMed ID: 19855220
    [No Abstract]   [Full Text] [Related]  

  • 11. [Reports. The psychopharmacological off-label prescribing in the treatment of children and adolescents with psychiatric disorders].
    Oehler KU; Romanos M; Uzelli-Schwarz O; Dieffenbach R; Vulturius G; Holtmann M; Wewetzer C
    Z Kinder Jugendpsychiatr Psychother; 2016; 44(4):315-7. PubMed ID: 27434690
    [No Abstract]   [Full Text] [Related]  

  • 12. Who are the PDCO?
    Dempsey EM; Connolly K
    Eur J Pediatr; 2014 Feb; 173(2):233-5. PubMed ID: 23925423
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Predictors of polypharmacy and off-label prescribing of psychotropic medications: a national survey of child and adolescent psychiatrists.
    Kearns MA; Hawley KM
    J Psychiatr Pract; 2014 Nov; 20(6):438-47. PubMed ID: 25406048
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Psychodynamic perspectives on psychotropic medications for children and adolescents.
    Chubinsky P; Hojman H
    Child Adolesc Psychiatr Clin N Am; 2013 Apr; 22(2):351-66. PubMed ID: 23538017
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Off-label use of drugs in psychiatry and neurology].
    Wallesch CW
    Fortschr Neurol Psychiatr; 2004 May; 72(5):243-4. PubMed ID: 15136944
    [No Abstract]   [Full Text] [Related]  

  • 16. Unmet needs in paediatric psychopharmacology: Present scenario and future perspectives.
    Persico AM; Arango C; Buitelaar JK; Correll CU; Glennon JC; Hoekstra PJ; Moreno C; Vitiello B; Vorstman J; Zuddas A;
    Eur Neuropsychopharmacol; 2015 Oct; 25(10):1513-31. PubMed ID: 26166453
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Pharmacovigilance in child and adolescent psychiatry].
    Egberts K; Karwautz A; Plener PL; Mehler-Wex C; Kölch M; Dang SY; Taurines R; Romanos M; Gerlach M
    Z Kinder Jugendpsychiatr Psychother; 2015 Jan; 43(1):21-8. PubMed ID: 25536893
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Drug monitoring and regulatory aspects of psychotropic drugs in childhood and adolescence].
    Hebebrand J; Gerlach M
    Z Kinder Jugendpsychiatr Psychother; 2009 Jul; 37(4):280-2. PubMed ID: 20306786
    [No Abstract]   [Full Text] [Related]  

  • 19. Therapeutic drug monitoring in child and adolescent psychiatry.
    Egberts KM; Mehler-Wex C; Gerlach M
    Pharmacopsychiatry; 2011 Sep; 44(6):249-53. PubMed ID: 21959786
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Restrictions on pharmaceutical detailing reduced off-label prescribing of antidepressants and antipsychotics in children.
    Larkin I; Ang D; Avorn J; Kesselheim AS
    Health Aff (Millwood); 2014 Jun; 33(6):1014-23. PubMed ID: 24889951
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.